Natera (NTRA) Expected to Announce Earnings on Thursday

Natera (NASDAQ:NTRA) is anticipated to post its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Natera to post earnings of ($0.53) per share and revenue of $616.9880 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same period last year, the company posted ($0.41) earnings per share. On average, analysts expect Natera to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Natera Stock Down 2.0%

Natera stock traded down $4.29 during mid-day trading on Tuesday, reaching $207.27. 772,071 shares of the company’s stock were exchanged, compared to its average volume of 1,217,914. The business’s fifty day simple moving average is $202.02 and its 200 day simple moving average is $214.32. The firm has a market capitalization of $29.49 billion, a PE ratio of -135.47 and a beta of 1.57. Natera has a one year low of $131.81 and a one year high of $256.36.

Insider Buying and Selling

In other news, CFO Michael Burkes Brophy sold 3,070 shares of Natera stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total value of $594,781.80. Following the completion of the transaction, the chief financial officer directly owned 58,291 shares in the company, valued at approximately $11,293,298.34. The trade was a 5.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 5,838 shares of Natera stock in a transaction on Monday, April 27th. The shares were sold at an average price of $204.14, for a total value of $1,191,769.32. Following the completion of the transaction, the chief executive officer owned 150,769 shares of the company’s stock, valued at approximately $30,777,983.66. This trade represents a 3.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 32,873 shares of company stock valued at $6,642,310 in the last ninety days. 5.63% of the stock is owned by company insiders.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after buying an additional 2,420,263 shares in the last quarter. State Street Corp grew its position in Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after buying an additional 72,087 shares in the last quarter. Coatue Management LLC grew its position in Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after buying an additional 2,463,008 shares in the last quarter. AQR Capital Management LLC grew its position in Natera by 8.3% during the fourth quarter. AQR Capital Management LLC now owns 2,599,299 shares of the medical research company’s stock worth $595,473,000 after buying an additional 199,234 shares in the last quarter. Finally, Invesco Ltd. grew its position in Natera by 8.9% during the fourth quarter. Invesco Ltd. now owns 1,329,166 shares of the medical research company’s stock worth $304,499,000 after buying an additional 108,437 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. William Blair assumed coverage on Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating for the company. Wells Fargo & Company raised their target price on Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Morgan Stanley decreased their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Finally, Citigroup assumed coverage on Natera in a research report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $253.47.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.